StemCell Therapy

UK based MR Solutions presented a simultaneous 7T PET/MRI preclinical imaging system optimized for nanoparticle imaging to the first joint annual congress of the French Nanomedicine Society (SFNano), and the French national Competency Cluster in Nanoscience CNano which was held in Dijon in early December.

Nanoparticles (NPs) have demonstrated great potential in diagnostic medicine particularly as contrast agents using MRI scanners. Iron oxide, gold, and gadolinium NPs have been used in preclinical and clinical studies as contrast enhancing agents.

The participants at the SFNano CNano 2019 joint meeting work in the scientific areas of nanomedicine, nanotechnology and nanoscience. MR Solutions presented the technology in a talk to the scientific community and displayed the PET/MRI system at the accompanying exhibition.

MR Solutions 7T PET/MR preclinical imaging system uses dry magnet, or liquid-helium free technology facilitating a compact system for multi-modality imaging. Researchers are able to combine high resolution MRI data with the high sensitivity of PET data for anatomical and quantitative studies.

Fabrice Chaumard, MR Solutions sales and marketing director commented: We were delighted that there was so much interest from the scientific community in our preclinical PET/MRI systems for nanoparticle imaging. This system provides much better imaging data and at a fraction of the cost of two separate systems.

The PET capability is provided by solid state detectors which are incorporated in the bore of the MRI scanner. The scanner combines the exquisite structural and functional characterisation of tissue provided by MRI with the extreme sensitivity of PET imaging for metabolism and tracking of uniquely labelled cell types or cell receptors. This is particularly useful in oncology, cardiology, and neurology research.

MR Solutions is the worlds leading independent developer and manufacturer of preclinical multi-modality MRI technology and remains the only company to deliver a commercial cryogen-free 3T to 9.4T range of compact MRI scanners. In recognition of the companys innovation and business acumen the company has received three Queens Awards for Enterprise for innovation in 2016 and 2019 and for international trade in 2017.

MR Solutions has over 30 years experience and in excess of 2000 installations across the world. This includes sales of their MRI spectrometers. Its scanners are renowned for their excellence in terms of superior soft tissue contrast and molecular imaging ability.

http://www.mrsolutions.com .

< Ends

Follow this link:
MR Solutions participates in the first nanomedicine joint annual meeting in Dijon - BioSpace

Elephants have many more cells than humans. However, they dont get cancer.

Eagles can see eight times the magnification of our own eyes. They also perceive ultraviolet light.

Bacteria defend themselves against viral attacks by cutting their own DNA.

Human beings can learn a lot from other living things as small as microbes, as large as elephants and whales.

And what better way to learn about what we can learn than by reading Michael Hehenbergers new book. The longtime Westport resident has just published Our Animal Connection.

In 339 pages, it explores the many ways we can learn about different species adaptations to extreme conditions, their evolution of special capabilities, and the ways they defend against predators and diseases. By studying the vast variety of life forms on earth particularly the top performers Hehenberger hopes that humans can learn and benefit.

Its a dense book, but the author knows his stuff. Hes spent a lifetime studying scientific questions, then coming up with solutions, and hes done it on both molecular and cosmic scales.

Born in Austria, Hehenberger earned a Ph.D. in quantum chemistry at the esteemed Uppsala University in Sweden. He worked for IBM in Europe, specializing in computational chemistry and biology, structural engineering, campus networks and high-performance computing. He moved in 1993 to their research center in San Jose, Calif.

Throughout his IBM career, Hehenberger led collaborations with academic and industrial life sciences organizations. The partnerships were based on joint desires to extend the frontiers of molecular biology, information-based medicine, bio-pharmaceutical research, unstructured data analytics, genomics and nanomedicine.

Three years later, he came east. IBM has facilities in Armonk, Yorktown Heights, White Plains and Somers, N.Y.. But, like many of the companys employees, he found Fairfield County taxes and housing better than Westchesters. He joined the large IBM contingent living in Westport.

His wife met a Wilton Road neighbor, Arlene Skutch, and took painting classes with her. Hehenberger traveled often, and was less involved in the town.

But when he retired in 2013, he joined the Ys Men. Like many retirees in that organization, he kept working. He formed the HM NanoMed Partnership, which organizes conferences and pursues nonomedical and genomic research topics.

And Hehenberger decided to write a book.

Nanomedicine: Science, Business, and Impact was published two years later. Hehenberger describes nanotechnologys intersection with life sciences and healthcare with depth and breadth.

His audience was politicians and businesspeople, including pharmaceutical and biotech executives. The book good excellent feedback. But his publisher priced it high nearly $100 so sales were limited.

Hehenbergers daughter, who has worked with Johnson & Johnson, McKinsey and Harvard, has diabetes. Insulin was first extracted from pigs and cattle. Hehenberger donated a kidney to his daughter, but knows that additional help in fighting the disease could come from animals.

He planned his next book the one about what we can learn from animals as a collaborative effort with a colleague, Zhi Xia, and his daughter. But she got busy, starting a company for patients with chronic diseases, and raising a child, so only he and Zhi worked together.

Zhi is co-founder of BGI, one of the worlds foremost genome sequencing companies. He has published dozens of academic papers and 14 books. They are professional colleagues and share a love for mountains too. Together, theyve traveled to Tibet and the Mount Everest base camp.

The message of their new book, which just started shipping, is simple, Hehenberger says: We need to respect animals, and all living organisms. We can learn a lot from them.

While the human brain is impressive, he notes enabling us to invent microscopes to study tiny organisms and telescopes to search the universe our visual perception cant compare to birds of prey, or even certain insects.

Although we are proud of our ability to run, jump, swim and climb mountains, our best Olympic performances lag behind potential animal competitors.

Our resistance to diseases and the way we recover from injuries are other areas where human performance is not always iimpressive.

The audience for Our Animal Connection is, the author says, anyone interested in animals, science, evolution and our planet.

Unfortunately, it too is priced high: $75.95 for hardcover and $79.95 for Kindle. Hehenberger worries it wont reach as many readers as hed like (hes working on discounts: email mhehen@gmail.com. Hes also hoping for a paperback edition).

As for his passion for mountains, Hehenberger is in the process of comparing the DNA of legendary climbers, like Tibetans, with those of people who live at lower altitudes. The way that mountain dwellers have evolved to deal with hypoxia may have relevance for COPD and cancer.

Who knows? It may also be the subject of his next book.

Dan Woog is a Westport writer, and his Woog's World appears each Friday. He can be reached at dwoog@optonline.net. His personal blog is danwoog06880.com.

Read this article:
Woogs World: Lots to learn from Westporters new book - Westport News

Nanomedicine Market

Global Nanomedicine Market Professional Survey Report 2019 share manufacturing companies, product type, technological progress, geographical regions, and applications 2019-2024. The Nanomedicine report looks thoroughly at company strategies, and marketing, expenditure, company planning, and sales. The outlook of this sector has been examined in conjunction with the many challenges and growth opportunities. The Nanomedicine analysis exhibits a strategic report and providing market intelligence that is accurate, trusted and vital for its merchants or to implicitly any organization.

Major Players in Nanomedicine market are:Company 1Company 2Company 3Company 4Company 5Company 6Company 7Company 8Company 9Company 10

Most important types of Nanomedicine products covered in this report are:Type 1Type 2Type 3Type 4Type 5

Most widely used downstream fields of Nanomedicine market covered in this report are:Application 1Application 2Application 3Application 4Application 5

Overview of the Report:The report begins with a market overview and moves on to cover the growth prospects of the Nanomedicine markets. Global Nanomedicine industry 2019 is a comprehensive, professional report delivering market research data that is relevant for new market entrants or established players. Key strategies of the companies operating in the markets and their impact analysis have been included in the report. Furthermore, a business overview, revenue share, and SWOT analysis of theleading players in the Nanomedicine market are available in the report.

Nanomedicine Market: Regional Analysis Includes:

Target Audience of Nanomedicine Market 2019 Forecast to 2024 Market:

The content of the study subjects, includes a total of 15 chapters:

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Contact Us:Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221, IN +919881074592

This post was originally published on Market Research Sheets

The rest is here:
Nanomedicine Market Global Industry to Record Significant Growth in the Near Future 2019-2024 - Market Research Sheets

LOS ANGELES, Dec. 17, 2019 /PRNewswire/ -- Immix Biopharma, Inc., announced today the first closing of a convertible note financing to support the clinical testing of its lead compound Imx-110 in advanced solid tumors. Mesa Verde managing director, Carey Ng, PhD, MBA, also joined the Board.

Immix CEO, Ilya Rachman, MD, PhD, MBA, shared, "We are thrilled to bring on Mesa Verde and Carey as we continue to build our team with executives and board members with successful experience in guiding early-stage clinical companies through similar phases of rapid growth."

With this additional funding, Immix will begin enrolling patients at US-based sites in its study testing Imx-110 in a Phase 1b/2a trial in advanced solid tumors. Immix received IRB approval to begin dosing patients at Synergy Hematology Oncology with offices in Los Angeles and Encino, CA. Dr. Levon Qasabian, MD will be the principal investigator, who stated that, "We are excited to explore the potential of this promising drug and offer it to patients with advanced tumors and limited treatment options."

Interim readouts from the Phase 1b/2a trial in Australia are 100% clinical benefit rate (akin to disease control rate) for all patients who completed the 5th cohort and at least 2 cycles as scheduled - with the longest duration of response being 8-months of stable disease. No treatment-related serious adverse events have been observed to-date and dose escalation is continuing. For information about participating in this study, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03382340

Immix is also opening a call for investigator initiated studies where the company will provide its lead compound Imx-110 at no charge.

About Imx-110Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration.

About the CompanyImmix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix's founding investor is a family office focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit http://www.immixbio.com.

Media ContactRyan Witt+1 (888) 958-1084info@immixbio.com

View original content:http://www.prnewswire.com/news-releases/immix-adds-biotech-vc-mesa-verde-to-investor-syndicate-and-receives-irb-approval-to-enroll-patients-in-phase-1b2a-cancer-study-in-the-united-states-300975006.html

SOURCE Immix Biopharma, Inc.

More:
Immix adds Biotech VC Mesa Verde to Investor Syndicate and Receives IRB Approval to Enroll Patients in Phase 1b/2a Cancer Study in the United States -...

The Nanomedicine research report is a valuable source of data for business strategists. It provides the Nanomedicine overview with growth analysis and historical and futuristic cost revenue demand and supply data. The research analysis provides an elaborative description of the value chain and distributor analysis.

Request Sample Copy of This Report: @https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/#Free-Sample-Report

The Nanomedicine market study provides comprehensive data that enhance the understanding, scope and application of this report.

The report provides a basic overview of the industry including definitions and classifications. The Nanomedicine analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Prominent players of Nanomedicine market:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc):

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

This report studies the Nanomedicine status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyses the top players in global market, and splits the Nanomedicine By product type and applications/end industries.

Read Detailed Index of full Research Study at @ https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/

To comprehend 2018-2026 Nanomedicine dynamics in the world mainly, the worldwide 2018-2026 Nanomedicine is analyzed across major global regions. Nanomedicine Also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, etc

The study objectives of this report are:

To study and forecast the market size of Nanomedicine

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end-use and region.

To analyses and compare the market status and forecast among global major regions.

To analyses the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting market growth.

TOC-

Check here for the discount@https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@99marketresearch.com), who will ensure that you get a report that suits your needs.

See the article here:
Nanomedicine Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 - Med News Ledger

The research report Healthcare Nanotechnology Market Global Industry Analysis 2019 2025 offers precise analytical information about the Healthcare Nanotechnology market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Healthcare Nanotechnology Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Healthcare Nanotechnology industry.

This Healthcare Nanotechnology market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Healthcare Nanotechnology market research report top-notch.

Interesting? Apply for a sample report: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-company-regions-491317#RequestSample

Competitive Landscape

Global Healthcare Nanotechnology market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International

Market Segmentation

Healthcare Nanotechnology Market report segmentation on Major Product Type:Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other

Market by Application: Here, various application segments of the global Healthcare Nanotechnology market are taken into account for the research study.

Anticancer, CNS Product, Anti-infective, Other

Enquire Here For Queries Or Report Customization: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-company-regions-491317#InquiryForBuying

Regional Analysis

The Healthcare Nanotechnology market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Healthcare Nanotechnology Market Report:-

What will the market growth rate, overview, and analysis by type of global Healthcare Nanotechnology Market in 2026?

What are the key factors driving, analysis by applications and countries Global Healthcare Nanotechnology Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Healthcare Nanotechnology Market?

Who are the opportunities, risk and driving forces of the global Healthcare Nanotechnology Market?

Who are the opportunities and threats faced by the vendors in the Global Healthcare Nanotechnology Market?

What are the Global Healthcare Nanotechnology market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Sorry! The Author has not filled his profile.

Read more:
Global Healthcare Nanotechnology Market 2019 by Company, Regions, Type and Application, Forecast to 2025 - Breaking News Updates

Since 1996, Carla Hutton has monitored, researched, and written about regulatory and legislative issues that may potentially affect Bergeson & Campbell, P.C. (B&C) clients. She is responsible for creating a number of monthly and quarterly regulatory updates for B&C's clients, as well as other documents, such as chemical-specific global assessments of regulatory developments and trends. She authors memoranda for B&C clients on regulatory and legislative developments, providing information that is focused, timely and applicable to client initiatives. These tasks have proven invaluable to many clients, keeping them aware and abreast of developing issues so that they can respond in kind and prepare for the future of their business.

Ms. Hutton brings a wealth of experience and judgment to her work in federal, state, and international chemical regulatory and legislative issues, including green chemistry, nanotechnology, the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the Toxic Substances Control Act (TSCA), Proposition 65, and the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) program.

Visit link:
Nanotoxicity Studies May Be Affected by Nanoparticles in Syringes - The National Law Review

A recent market study published by QY Research consists of a detailed assessment of the key market dynamics. The report provides the historical as well as present growth parameters of the global Nanobots market. The report features salient and unique factors, which are expected to significantly impact the growth of the global Nanobots market throughout the forecast period.

Scope of the report:

The report commences with a scope of the global Nanobots market that includes the key findings and vital statistics of the market. This market research report also consists of the market value of the major segments of the global Nanobots market. QY Research has found a detailed taxonomy and the definition of the global market that helps the readers to better understand the basic information of the Nanobots market. It also highlights the exclusions and inclusions that help the client to understand the scope of the Nanobots market.

The report consists of key market trends, which are likely to impact the growth of the market over the forecast period. Evaluation of in-depth industry trends is included in the report, along with their product innovations and key market growth.

QY Research report also includes the macro-economic factors, which are likely to influence the growth of the global Nanobots market during the forecast period. Along with the factors, the report also analyzes the growth opportunities of the global Nanobots market. It sheds light on the trends, restraints, and drivers to understand the growth prospects followed by the key players in the global Nanobots market.

Request For Sample of the Report:https://www.qyresearch.com/sample-form/form/894557/global-nanobots-industry-research-report-growth-trends-and-competitive-analysis-2018-2025

Competitive Landscape:

The report provides a list of all the key players in the Nanobots market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product development, research, and development, and also provides revenue shares, company overview, and recent company developments to remain competitive in the market.

The Nanobots key manufacturers in this market include:

Xidex CorpZymergen IncSynthace LimitedGinkgo BioworksAdvanced Diamond TechnologiesAdvanced Nano Products Co Limited

Segment Analysis:

The report provides detailed segments based on product type and applications so that the readers can better understand each segment that influences the Nanobots market growth.

By the product type, the market is primarily split into

Microbivore NanorobotsRespirocyte NanorobotsClottocyte NanorobotsCellular Repair Nanorobots

By the end users/application, this report covers the following segments

Nano MedicineBiomedicalMechanicalOther applications

Request For Customization of the Report:https://www.qyresearch.com/customize-request/form/894557/global-nanobots-industry-research-report-growth-trends-and-competitive-analysis-2018-2025

Geographical Outlook:

In 2018, the global Nanobots market size was increased to xx million US$ from xx million US$ in 2014, and it will reach xx million US$ in 2025, growing at CAGR of xx%% between 2019 and 2025.

QY Research report provides a detailed information to the clients about the various factors that are impacting on the growth of the regions across North America (United States, Canada and Mexico), Asia Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines and Vietnam), Middle East and Africa (Turkey, GCC Countries, Egypt and South Africa), and South America (Brazil and others).

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read More Reports:

http://www.marketwatch.com/story/trending-newscontinous-extrusion-machine-market-status-and-prospect-2019-2025-2019-11-26

Read More Reports:

https://www.openpr.com/news/1853458/global-food-manufacturing-and-processing-machinery-market-size

“Global Non-woven Table Linen Market Size Growth, Development and Opportunities in 2019-2025: Intexcomfort , Mungo , Jomar, Inc. , Linomeda etc.”

View original post here:
Global Nanobots Market Size by forecasting the high Growth Segments 2019-2025: Xidex Corp, Zymergen Inc, Synthace Limited, Ginkgo Bioworks, Advanced...

DUBLIN--(BUSINESS WIRE)--The "Nanobiotechnologies - Applications, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Nanotechnology is the creation and utilization of materials, devices, and systems through the control of matter on the nanometer-length scale (a nanometer is one billionth of a meter. Nanobiotechnology, an integration of physical sciences, molecular engineering, biology, chemistry and biotechnology holds considerable promise of advances in pharmaceuticals and healthcare.

The report starts with an introduction to various techniques and materials that are relevant to nanobiotechnology. It includes some of the physical forms of energy such as nanolasers. Some of the technologies are scaling down such as microfluidics to nanofluidic biochips and others are constructions from bottom up. Application in life sciences research, particularly at the cell level sets the stage for role of nanobiotechnology in healthcare in subsequent chapters.

Some of the earliest applications are in molecular diagnostics. Nanoparticles, particularly quantum dots, are playing important roles. In-vitro diagnostics, does not have any of the safety concerns associated with the fate of nanoparticles introduced into the human body. Numerous nanodevices and nanosystems for sequencing single molecules of DNA are feasible. Various nanodiagnostics that has been reviewed will improve the sensitivity and extend the present limits of molecular diagnostics.

An increase in the use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening.

Some of the nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.

Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems.

Nanotechnology will markedly improve the implants and tissue engineering approaches as well. Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as supply of purified water are also included.

There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter market, these are expected to be in place.

Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress.

There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2018. The largest expansion is expected between the years 2023 and 2028.

Profiles of 252 companies, out of over 500 involved in this area, are included in the last chapter along with their 185 collaborations. The report is supplemented with 51 Tables, 32 figures and 800 references to the literature.

For more information about this report visit https://www.researchandmarkets.com/r/lrcr1q

Read more here:
Nanobiotechnologies Applications, Markets & Companies Analysis 2019 - Updated Forecasts to 2023 & 2028 - ResearchAndMarkets.com - Business...

According to Stratistics MRC, the GlobalNanorobotics Marketis accounted for $4.10 Billion in 2017 and is expected to reach $11.88 Billion by 2026 growing at a CAGR of 12.5% during the forecast period. Growing application of nanotechnology and regenerative medicine, rising acceptance and preferment of entrepreneurship and increasing investments by government and universities are the key factors fuelling the market growth. However, high manufacturing cost may hinder the growth of the market.

Nanorobotics is an evolving technology arena that creates robots or machines which have machinery near to the scale of a nanometre (109 meters). It denotes the nanotechnology engineering regulation of planning, designing, and building nanorobots, primarily from molecular components. Nanorobotics is an attractive new field, especially in medicine, which focus on directed drug delivery using nanoscale molecular machines.

Request for Report sample:https://www.trendsmarketresearch.com/report/sample/11327

By Type, Nanomanipulator is expected to hold considerable market growth during the forecast period. Nanomanipulator is a specialized nanorobot and microscopic viewing system for working with objects on an extremely small scale. Nanomanipulators are mainly used to influence the atoms and molecules and were among the first nanorobotic systems to be commercially accessible. By geography, Europe dominated the highest market share due to rising aging population and rising governmental healthcare expenditure.

Some of the key players in Nanorobotics include Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract and Nanonics Imaging

Types Covered: Nanomanipulator Magnetically Guided Bacteria-Based Bio-Nanorobotics

Applications Covered: Biomedical Nanomedicine Mechanical Other Applications

Request for Report Discount :https://www.trendsmarketresearch.com/report/discount/11327

Regions Covered: North Americao USo Canadao Mexico Europeo Germanyo UKo Italyo Franceo Spaino Rest of Europe Asia Pacifico Japano Chinao Indiao Australiao New Zealando South Koreao Rest of Asia Pacific South Americao Argentinao Brazilo Chileo Rest of South America Middle East & Africao Saudi Arabiao UAEo Qataro South Africao Rest of Middle East & Africa

What our report offers: Market share assessments for the regional and country level segments Market share analysis of the top industry players Strategic recommendations for the new entrants Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with detailed strategies, financials, and recent developments Supply chain trends mapping the latest technological advancements

Free Customization Offerings:All the customers of this report will be entitled to receive one of the following free customization options: Company Profilingo Comprehensive profiling of additional market players (up to 3)o SWOT Analysis of key players (up to 3) Regional Segmentationo Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check) Competitive Benchmarkingo Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Read the original here:
Nanorobotics Market to receive overwhelming hike in Revenues by 2026 - Guru Online News

Newest Learn about at the International Nanomedicine Market

The lately printed record via Transparency Market Analysis at the world Nanomedicine marketplace provides resourceful insights referring to the long run possibilities of the Nanomedicine marketplace. The underlying developments, enlargement alternatives, impeding elements, and evident marketplace drivers are totally studied within the introduced record.

As in keeping with the record, the worldwide Nanomedicine marketplace is projected to develop at a CAGR of ~XX% and exceed the worth of ~US$ against the tip of 2029. Additionally, an in-intensity research of the micro and macro-financial elements which are expected to steer the trajectory of the Nanomedicine marketplace all through the forecast length (2019-2029) is integrated within the record.

Experiences are to be had at discounted charges! Be offering expires quickly!

Request For Bargain On This Document @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=1753

Important Insights Associated with the Nanomedicine Market within the Document:

Nanomedicine Market Segments

A radical analysis of the long run possibilities of the Nanomedicine marketplace throughout more than a few areas is tracked within the record.

segmentation, and demanding situations out there were mentioned at duration within the analysis record.

Review of the Cloud Computing Market in Healthcare Trade

As in keeping with the analysis record, the worldwide marketplace for cloud computing within the healthcare business used to be valued at US$1.82 bn in 2011 and is projected to succeed in a worth of US$6.79 bn via the tip of 2018. The marketplace is projected to sign up a exceptional 21.30% CAGR between 2012 and 2018.

The safety of get entry to and knowledge integrity and several other different advantages presented via cloud computing are estimated to inspire the expansion of the marketplace in the following couple of years. Alternatively, information leakage considerations, information integration and consistency, and knowledge relocation are one of the key elements estimated to restrain the expansion of the worldwide cloud computing marketplace within the healthcare business in the following couple of years.

At the moment, the instrument-as-a-provider phase leads the worldwide cloud computing marketplace within the healthcare business. However, the platform-as-a-provider phase is estimated to witness considerable enlargement within the coming years. Moreover, at the foundation of finish use, the non-scientific knowledge techniques marketplace is projected to guide the worldwide marketplace within the close to long run.

A number of the key geographical segments, North The usa is estimated develop at a swift tempo and account for an enormous proportion within the world marketplace for cloud computing within the healthcare business in the following couple of years. The top enlargement of this area may also be attributed to the presence of numerous biopharmaceutical gamers. As well as, the emerging focal point on analysis and construction actions is anticipated to give a contribution widely against the expansion of the marketplace.

Firms Discussed within the Analysis Document

The world marketplace for cloud computing within the healthcare business is very fragmented in nature as no key gamers grasp greater than a proportion of 10% out there at this time. CareCloud, ClearDATA Networks, Oracle Company, Microsoft, Agfa Healthcare, IBM Company, and Merge Healthcare are one of the key gamers running within the world cloud computing marketplace within the healthcare business.

Key Segments of the International Cloud Computing marketplace in Healthcare Trade

International Cloud Computing marketplace in Healthcare Trade, via provider fashions

International Cloud Computing marketplace in Healthcare Trade, via pricing fashions

International Cloud Computing marketplace in Healthcare Trade, via finish customers

International Cloud Computing marketplace in Healthcare Trade, via Geography

This record provides you with get entry to to decisive information equivalent to:

Key highlights of this record

Request Pattern Document @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=1753

Essential queries associated with the Nanomedicine marketplace addressed within the record:

Why Make a selection TMR?

RequestTOC For ThisDocument @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=1753

See original here:
Robust Growth Of The Nanomedicine Market Predicted Over The Forecast Period 2013 - 2019 - Hitz Dairies

Yuehe Lin

Yuehe Lin, professor in the School of Mechanical and Materials Engineering, has been named a fellow of the National Academy of Inventors (NAI).

He was cited for his highly prolific spirit of innovation in creating or facilitating inventions that have made a tangible impact on the quality of life, economic development, and welfare of society, according to the selection committee. Lin is one of 168 NAI Fellows for 2019, which is the highest professional distinction accorded solely to academic inventors. The program includes more than 1,000 fellows from 250 universities around the world that hold more than 41,500 U.S. patents.

Dr Lin has made significant research contributions with real-world impact in the fields of energy and health, said Mary Rezac, dean of WSUs Voiland College of Engineering and Architecture. His hugely varied work from finding possible new ways to treat cancer to innovations in water splitting for a future hydrogen economy and development of a better catalyst for fuel cells often comes down to simple solutions that can provide real change and improvements in peoples lives.

With WSU since 2013, Lin, who also holds a joint appointment at Pacific Northwest National Laboratory, conducts research in nanotechnology, particularly development of small-scale devices, materials and analytical systems for biomedical diagnosis, drug delivery and energy and environmental applications.

He has more than 500 peer-reviewed publications, which have been cited more than 50,500 times, according to Google Scholar. He has an h-index, a measure of a scientists productivity and impact, of 112. He has been named among the worlds most highly cited researchers every year from 2014 to 2019 by the Web of Science Group.

He has received funding from the National Institutes of Health, U.S. Centers for Disease Control and Prevention and U.S. Departments of Energy and Defense. He holds more than 20 patents, some of which have been licensed to industrial partners for commercialization.

Lin is a fellow of the American Association for the Advancement of Science, Royal Society of Chemistry and American Institute of Medical and Biological Engineering as well as a member of the Washington State Academy of Sciences. He serves as editor or editorial board member for approximately 20 international journals, including Advance Materials Technologies; Analytica Chimica Acta; Biosensors and Bioelectronics; Electroanalysis; International Journal of Nanomedicine; Research; Journal of Nanoscience and Nanotechnology; and Sensors and Actuators B.

Lin will join the induction ceremony for fellows on April 10 as part of the annual Conference of the National Academy of Inventors in Phoenix, AZ.

Read the original post:
Yuehe Lin named to National Academy of Inventors - WSU News

The Healthcare Nanotechnology Market report gives a purposeful depiction of the area by the practice for research, amalgamation, and review of data taken from various sources. The market analysts have displayed the different sidelines of the area with a point on recognizing the top players (Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International) of the industry. The Healthcare Nanotechnology market report correspondingly joins a predefined business market from a SWOT investigation of the real players. Thus, the data summarized out is, no matter how you look at it is, reliable and the result of expansive research.

This report mulls over Healthcare Nanotechnology showcase on the classification, for instance, application, concords, innovations, income, improvement rate, import, and others (Anticancer, CNS Product, Anti-infective, Other) in the estimated time from 20192025 on a global stage. In like manner, the overall Healthcare Nanotechnology market report reveals knowledge identified with the type of product, its applications, customers, prime players, and various components agreeing with the account. This first data demonstrates critical contenders and their definite picture of the general Healthcare Nanotechnology market. Other than this, the report further demonstrates expected market power, challenges, and prospects in the Healthcare Nanotechnology market.

Request for Sample Report @www.intenseresearch.com/market-analysis/global-healthcare-nanotechnology-market-2019-by-manufacturers-countries.html#request-sample

The report gives a broad explanation of the presence of the Healthcare Nanotechnology market in different regions and countries. With an extensive regional analysis of the Healthcare Nanotechnology market, the research analysts make an attempt to unveil hidden growth prospects available for players in different parts of the world. They accurately estimate market share, CAGR, production, consumption, price, revenue, and other crucial factors that indicate the growth of regional markets studied in the report. They also shed light on the presence of prominent players in regional markets, and how it is making a difference in the growth of the regional markets. The main objectives of the research report elaborate the overall market overview on Healthcare Nanotechnology market dynamics, historic volume and value, robust market methodology, current & future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure, government policies & regulations, etc.

Healthcare Nanotechnology Market report segmentation on Major Product Type:Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other

The global version of this report with a geographical classification such as

North America (the United States, Canada, and Mexico)Europe (Germany, UK, France, Italy, Russia, Spain, and Benelux)Asia Pacific (China, Japan, India, Southeast Asia, and Australia)Latin America (Brazil, Argentina, and Colombia)The Middle East and Africa

Reason to buy Healthcare Nanotechnology Market Report : 1) Breakdown of the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.2) The Healthcare Nanotechnology competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.3) Describe Healthcare Nanotechnology sales channel, distributors, customers, research findings and conclusion, appendix and data source.4) The details of the competitive landscape outlined in this report are likely to provide an analysis of the prominent industry vendors, their growth profiles, strategies, and tactics, etc., that would help investors in decision-making.5) To project the size of Healthcare Nanotechnology submarkets, with respect to key regions (along with their respective key countries).6) To strategically profile the key players and comprehensively analyze their growth strategies.7) Focuses on the key global Healthcare Nanotechnology players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in the next few years.

This report contributes an overall summary of the global Healthcare Nanotechnology market, including business perspectives, market strategies, assembles data related to various business firms, its year of establishment, contact information, market outline, sales revenue, industry segments, the business most prestigious location, and regional presence. The report includes several plans and policies related to the Healthcare Nanotechnology industry, moreover, it describes the management process, product appearance, manufacturing cost, and market volume. In addition, the global Healthcare Nanotechnology market report implicates financial usage, the quantity of product, chain format, demand and supply ratio. This report justifies the various business trends followed by the marketing sectors as well as the distributors of the Healthcare Nanotechnology industry.

Inquiry for Buying a report @www.intenseresearch.com/market-analysis/global-healthcare-nanotechnology-market-2019-by-manufacturers-countries.html#inquiry-for-buying

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, the growth rate of the Healthcare Nanotechnology market in 2023 is also explained. Finally, the possibility analysis of new project investment is done in the report, which contains a comprehensive SWOT analysis of the Healthcare Nanotechnology market.

Sorry! The Author has not filled his profile.

Excerpt from:
Global Healthcare Nanotechnology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Global Market News 24

Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) -- The "Biomarkers: Discovery Techniques and Applications - A Global Market Overview 2019" report has been added to ResearchAndMarkets.com's offering.

The report reviews analyzes and projects the global Biomarkers market for the period 2016-2025 in terms of market value in US$ and the compound annual growth rates (CAGRs) projected from 2018 through 2025.

The global market for Biomarkers is dominated by Oncology, in terms of application, estimated at a market share of 41.2% in 2018 and forecast to touch US$15.6 billion in 2019. The overall market for Biomarkers is projected to reach approximately US$50 billion by 2021.

The factors driving the Biomarkers market growth includes elevated demand for personalized medicine, technological advancement, immense utilization of biomarkers in drug discovery and development procedures, massive research on biomarkers, increasing awareness about the role of biomarkers in early disease diagnosis, increase research funding, and many more

Research Findings & Coverage

Key Market Trends

For more information about this report visit https://www.researchandmarkets.com/r/9jqzri

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Excerpt from:
Analysis on the World Market for Biomarkers 2016-2019 & 2025: Key Trends, Discovery Techniques & Applications - Yahoo Finance

Credit: ACS Appl. Mater. Interfaces

An array of platinum nanostraws can be used to deliver molecules to cells or sample their contents.

Hollow nanosized needles, or nanostraws, are a promising tool for opening up tiny, temporary holes in cell membranes to deliver molecules or sample a cells contents. Nanostraws could also deliver gene editors into cells for immunotherapy, cutting the need to use costly viruses for the job. But making nanostraws requires expensive manufacturing equipment in a clean room facility, and using nanostraws often requires applying a high voltage in order to open up the cell membrane. Now, researchers have developed a more affordable fabrication approach that can be done in an ordinary lab. Whats more, the new nanostraws are conductive, thus lowering the amount of voltage needed to levels less likely to damage cells (ACS Appl. Mater. Interfaces 2019, DOI: 10.1021/acsami.9b15619).

Researchers made earlier iterations of nanostraws with atomic layer deposition (ALD), which grows thin films of materials such as metal oxides one layer of atoms at a time. In their new approach, Xi Xie of Sun Yat-Sen University and colleagues replaced ALD with electroplating, a simple process which uses an electrical potential to deposit ions in a solution onto a surface.

Sign up for C&EN's must-read weekly newsletter

They first sputtered a thin layer of gold on the bottom surface of a polycarbonate template containing an array of pores in order to make a conductive base layer. Then they electroplated platinum, gold, or the conductive polymer poly(3,4-ethylenedioxythiophene)three common materials used in electrophysiology studiesfrom the top. The materials lined the pores of the template, creating the hollow nanostraws. The team then used mechanical polishing and oxygen plasma etching to remove the polycarbonate template, revealing an array of vertical nanostraws, each a few hundred nanometers in diameter. According to Xie, their method can work with templates of various pore sizes or pore densities, or with other plating materials.

Ciro Chiappini, a nanomedicine researcher at Kings College London, says this study is a needed and significant step toward developing affordable nanostraws.

Using a representative platinum nanostraw array, Xie and colleagues demonstrated that they could deliver a fluorescent dye into cultured human cells and extract intracellular materials to examine how the levels of an enzyme changed over time.

The conductivity of the new nanostraws allowed the researchers to open tiny pores in the cell membrane by applying a voltage of only 35 V, a safer range for cells compared with 1020 V needed when using nonconductive nanostraws.

These straws could make cellular treatments such as CAR-T therapy faster, safer, and cheaper, says Nicholas A. Melosh, a materials scientist at Stanford University who has done nanostraw research. Typical immunotherapy delivers therapy to a patients immune cells using viruses, which is costly and carries the risk of dangerous immune responses once the cells are put back into the patient, he says. Nanostraws could potentially deliver the necessary therapies to cells without the need for viruses.

See the rest here:
Electroplating method makes conductive nanostraws for injecting into and sampling from cells - Chemical & Engineering News

Share

Share

Email

Metal nanoclusters, made up of several to one hundred metal atoms (e.g., Au, Ag, Cu, Pt), are a novel class of intermediate between metal atoms and nanoparticles. As their size (<2 nm) borders on the Fermi wavelength of electrons, metal nanoclusters possess strong photoluminescence in comparison with large metal nanoparticles (>2 nm). This, combined with tunable fluorescence emissions, high photostability, good quantum yields and facile synthesis, make them excellent fluorescent labels for biomedical applications.

However, the reduction of metal ions in liquid solution during synthesis usually causes large nanoparticles rather than small metal nanocluster formation because of their tendency to aggregate. In light of this, proteins whose thiol, amino, and carboxyl groups have a strong affinity for metal atoms are typically used to stabilize metal nanoclusters to protect them from aggregationthese proctected clusters are commonly called protein-protected metal nanoclusters.

Protein-protected metal nanoclusters have excellent biocompatibility and have received considerable attention as a luminescent probe in a number of fields such as biosensing, bioimaging, and imaging-guided therapy. However, apart from unique optical properties, protein-protected metal nanoclusters also possess interesting biological properties such as enzyme-like activity similar to that of natural enzymes; until recently, this has been an overlooked quality that is starting to shine in basic research and practical applications.

Nanozymes is a new termed used to refer to nanomaterials with intrinsic enzyme-like activity. Since professor Yan and coworkers first discovered that nanoparticleswhich are traditionally assumed to be inertpossessed intrinsic enzyme-like activity, a substantial amount of work has focused on further developing and harnessing the advantageous properties of nanozymes, which include high catalytic ability, high stability, and low cost. Nowadays, more than 540 kinds of nanomaterials, which possess intrinsic enzymatic activity, have been reported from 350 laboratories in 30 countries and have been used in biological analysis, environmental treatment, as antibacterial agents, cancer therapy, and antioxidation therapy.

In a recent study published in WIREs Nanomedicine and Nanobiotechnology, Professor Xiyun Yan and Kelong Fan explore the newly developing field of biologically active protein-protected metal nanoclusters, namely those that possess peroxidase, oxidase, and catalase activities, and are consequently used for biological analysis and environmental treatment.

An intriguing example of this is bovine serum albumin-protected gold (Au) nanoclusters, which exhibit peroxidase enzymatic activity to catalyze the oxidation of colored organic substrates, which is currently carried out using natural peroxidases. This method showed an advantage over the natural peroxidase-based methods because bovine serum albumin-protected Au nanoclusters exhibited higher robustness and retained enzymatic activity over a wide range of pH and temperatures. In another example, lysozyme-protected platinum (Pt) nanoclusters exhibit oxidase enzymatic activity which has been applied to the oxidative degradation of pollutants, such as methylene blue in lake water.

The proteins themselves not only provide protection and stabilization during synthesis, but can also provide a myriad of other functions to the nanoclusters. Proteins have been shown to enable in vivo applications because of their enhanced biocompatibility. In fact, a protease-responsive sensor for in vivo disease monitoring was designed by utilizing the peroxidase activity of peptide-protected Au nanoclusters and their ultra-small size dependent tumor accumulation and renal clearance properties.

The sensor was developed using peptides which are the substrates/targets of disease related proteases as protective ligands to synthesis the Au nanoclusters nanozymes, which were then conjugated to a carrier. After reaching the site of disease, the sensor was disassembled in response to the dysregulated protease and the liberated Au nanoclusters were filtered through the kidneys and into urine to produce a rapid and sensitive colorimetric readout of diseases state. By employing different enzymatic substrate as protective ligands for Au nanoclusters, this modular approach could enable the rapid detection of a diverse range of diseases with dysregulated protease activities such as cancer, inflammation, and thrombosis.

These findings have extended the horizon of protein-protected metal nanoclusters properties as well as their application in various fields, says Kelong Fan. Furthermore, in the field of nanozymes, protein-protected metal nanoclusters have emerged as an outstanding new addition. Due to their ultra-small size (<2 nm), they usually have higher catalytic activity, more suitable size for in vivo application, better biocompatibility and photoluminescence in comparison with large size nanozymes. We think that ultra-small nanozymes based on protein-protected MNCs are on the verge of attracting great interest across various disciplines and will stimulate research in the fields of nanotechnology and biology.

Despite the advantages and advancedprogress in the development of protein-protected metal nanoclusters asultra-small nanozymes, there are still some challenges that need to be addressedin future work.

First, most researchers still only rely on bovine serum albumin as both the reducing agent and stabilizer. Since we know that protein-protected metal nanoclusters may retain the bioactivity of the protein ligand, it is necessary to explore methods for synthesizing other new protein-protected metal nanoclusters, which will widen the diagnostic and therapeutic applications of protein-protected metal nanoclusters nanozymes.

Second, there are six types of catalytic reactions in nature: oxidoreductases, transferases, hydrolases, isomerases, ligases, and lyases. Thus far, although many protein-protected metal nanoclusters have demonstrated enzyme activities they all are oxidoreductase-like activities such as peroxidase, oxidase, and catalase. Therefore, there is a ample room to develop other types of nanozymes based on protein-protected metal nanoclusters. In this regard, more understanding of the structures and catalytic mechanisms of protein-protected metal nanoclusters is required in addition to the deeper understanding on natural enzymes themselves.

Third, a considerable number of reports have suggested that ultra-small nanozymes based on protein-protected metal nanoclusters are promising tools for biological analysis. However, little is known about the therapeutic function of these ultra-small clusters in vivo despite their advantages of suitable size and good biocompatibility. It is well known that peroxidase, oxidase, and catalase are main enzymes in biological systems involved in the maintenance of redox homeostasis. Thus, more attention should be paid to the usage of these ultra-small nanozymes based on protein-protected metal nanoclusters as bio-catalysts in various human diseases involved in redox dysregulation such as cancer, inflammation, cardiovascular diseases. It is also possible to employ the products of redox nanozymes to treat other diseases, for example, use the toxic hydroxyl radicals produced by peroxidase nanozymes to treat bacterial infection.

Overall, there is still much room for future research and application of ultra-small nanozymes based on protein-protected metal nanoclusters. It is expected that the enzyme-like activity of protein-protected metal nanoclusters will certainly attract broader interests across various disciplines and stimulate research in the fields of nanotechnology and biology, making these emerging ultra-small nanozymes become novel multifunctional nanomaterials for a number of biomedical applications.

Kindly contributed by the authors.

Read the original here:
Protein-Protected Metal Nanoclusters That Behave Like Natural Enzymes - Advanced Science News

Fatima Aouidat,1 Sarah Boumati,2 Memona Khan,1 Frederik Tielens,3 Bich-Thuy Doan,2 Jolanda Spadavecchia1

1CNRS, UMR 7244, CSPBAT, Laboratory of Chemistry, Structures and Properties of Biomaterials And Therapeutic Agents University Paris 13, Sorbonne Paris Cit, Bobigny, France; 2UTCBS Chimie ParisTech University Paris Descartes - CNRS UMR 8258 INSERM U1022 Equipe Synthesis, Electrochemistry, Imaging and Analytical Systems for Diagnostics SEISAD, Paris, France; 3General Chemistry (ALGC), Vrije University of Brussel (Free University Brussels-VUB), Brussel, Belgium

Correspondence: Jolanda Spadavecchia Email jolanda.spadavecchia@univ-paris13.fr

Introduction: The development of biopolymers for the synthesis of Gd(III) nanoparticles, as therapeutics, could play a key role in nanomedicine. Biocompatible polymers are not only used for complex monovalent biomolecules, but also for the realization of multivalent active targeting materials as diagnostic and/or therapeutic hybrid nanoparticles. In this article, it was reported for the first time, a novel synthesis of Gd(III)biopolymerAu(III) complex, acting as a key ingredient of core-shell gold nanoparticles (Gd(@AuNPs).Material and methods: The physical and chemical evaluation was carried out by spectroscopic analytical techniques (Raman spectroscopy, UV-visible and TEM). The theoretical characterization by DFT (density functional theory) analysis was carried out under specific conditions to investigate the interaction between the Au and the Gd precursors, during the first nucleation step. Magnetic features with relaxivity measurements at 7T were also performed as well as cytotoxicity studies on hepatocyte cell lines for biocompatibility studies. The in vivo detailed dynamic biodistribution studies in mice to characterize the potential applications for biology as MRI contrast agents were then achieved.Results: Physicalchemical evaluation confirms the successful design and reaction supposed. Viabilities of TIB-75 (hepatocytes) cells were evaluated using Alamar blue cytotoxic tests with increasing concentrations of nanoparticles. In vivo biodistribution studies were then accomplished to assess the kinetic behavior of the nanoparticles in mice and characterize their stealthiness property after intravenous injection.Conclusion: We demonstrated that Gd@AuNPs have some advantages to display hepatocytes in the liver. Particularly, these nanoconjugates give a good cellular uptake of several quantities of Gd@NPs into cells, while preserving a T1 contrast inside cells that provide a robust in vivo detection using T1-weighted MR images. These results will strengthen the role of gadolinium as complex to gold in order to tune Gd(@AuNPs) as an innovative diagnostic agent in the field of nanomedicine.

Keywords: Gd-gold complex, theoretical study, MRI, relaxivity, biodistribution

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Originally posted here:
Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Co | IJN - Dove Medical Press

DUBLIN--(BUSINESS WIRE)--Dec 3, 2019--

The "Biochips - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for the estimation of markets.

Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA. Separate chapters are devoted to protein biochips/microarrays, microfluidics and nanobiotechnology-based nano-arrays.

Various applications of biochips and microarrays are described throughout the report. Areas of application such as point-of-care, genetic screening, cancer, and diagnosis of infections are included. Separate chapters are devoted to applications in drug discovery and development as well as personalized medicine

The report provides current share of each segment: market size in 2018 and projected value for the years 2023 and 2028. Gene expression has the largest share and is an established market. Share of microarray technologies in other areas will grow with the maximum growth in RNA splice variants followed by epigenetics.

The growth in protein microarrays is somewhat less, partly because it is more mature than the other submarkets and has already shown considerable growth in the past. The impact of next generation sequencing on segments of microarray markets is identified. Customer requirements and unmet needs are described. Markets are also analyzed according to geographical areas.

Brief profiles of companies involved in biochip/microarray technologies are provided. Currently selected 94 companies are included along with a listing of 121 collaborations between companies. The text is supplemented by 21 tables, 11 figures and 140 references to literature.

Key Topics Covered:

0. Executive Summary

1. Introduction

Definitions of biochips/microarray

Terms used for biochips

Historical aspects of biochip/microarray technology

Relation of microarrays to other technologies

Applications of biochips/microarrays

Advantages of biochips/microarrays

2. Biochip and Microarray Technologies

Introduction

Nucleic acid amplification and microarrays

PCR on a chip

Fast PCR biochip

Multiplex microarray-enhanced PCR for DNA analysis

Universal DNA microarray combining PCR and ligase detection reaction

NASBA combined with microarray

Rolling circle amplification on microarrays

LiquiChip-RCAT

Multiplexed Molecular Profiling

Genomewide association scans

Whole genome microarrays

GeneChip Human Genome Arrays

Arrayit's H25K

Transposon insertion site profiling chip

Standardizing the microarrays

Optical Mapping

Imaging technologies used for detection in biochips/microarray

Fluorescence and chemiluminescence

MALDI-MS imaging and tissue microarrays

Surface plasmon resonance technology for microarrays

Microarray imaging systems

Vidia Microarray Imaging Systems

GenePix 4100A Microarray Scanner

Tecan LS Reloaded

Microarrays based on detection by physico-chemical methods

Electrical biochips

Photoelectrochemical synthesis of DNA microarrays

Microchip capillary electrophoresis

Strand displacement amplification on a biochip

Biosensor technologies for biochips

DNA-based biosensors

Arrayed Imaging Reflectometry

Digital electronic biosensor chips

Phototransistor biochip biosensor

Applications of biosensor biochips

Biosensors in food safety

Cholesterol biosensor

Glucose biosensors

Biochips and microarrays for cytogenetics

Chromosomal microarrays

Comparative genomic hybridization

Array-based CGH

NimbleGen CGH arrays

Single-cell array CGH

Regulatory requirements for array CGH

Combination of FISH and gene chips

Combination of CGH and SNP microarray platforms

Fish-on-chip

SignatureChip

Tissue microarrays

Pathology tissue-ChIP

Carbohydrate microarrays

RNA profiling

RNA splice variants

RIP-Chip

miRNAs

Microarrays for miRNAs

Microarrays vs qPCR for measuring miRNAs

Quantitative analysis of miRNAs in tissue microarrays by ISH

Exon microarrays

Microarrays & DNA sequencing

Microarray-based emerging DNA sequencing technologies

Exome sequencing for study of human variation

High-throughput array-based resequencing

Sequencing by hybridization

SOLiD-System based ChIP-Sequencing

Next generation sequencing vs microarrays for expression profiling

Microarrays for synthetic biology

Arrayit microarray platform for synthetic biology

Microarray-based gene synthesis

Magnetophoretic array-based cell sorting for further studies

3. Microfluidics-based Biochips and Microarrays

Introduction

Use of technologies from other industries in microfluidics

Digital dispensing

Lab-on-a-chip

Amplification of fluorescence signal from lab-on-a-chip

Use of glass in microfluidics

LabChip

LabCD

Lab-on-a-brain

Go here to see the original:
Biochips Technologies, Companies, Applications & Markets, 2028 - 94 Companies are Included Along with a Listing of 121 Collaborations Between...

Dec. 3, 2019 14:48 UTC

BOSTON--(BUSINESS WIRE)-- Today, InvicroLLC, a Konica Minolta Company, has joined Accentures open partner ecosystemthe INTIENT Networkwhich is designed to help solution providers, software vendors and life sciences companies team more effectively to accelerate drug discovery and improve patient outcomes. Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development.

The INTIENT Network is an integral part of INTIENT Research, Accentures cloud-based informatics suite that is focused on improving productivity, efficiency and innovation in the drug discovery process. Accenture is currently working with a select number of independent software vendors and organizations, including Invicro, to integrate their technology and content into the INTIENT platform.

Through the INTIENT Network, research scientists can access Invicros industry-leading imaging software platforms, iPACS and VivoQuant, that help transform the way translational medicine research is conducted. Invicro joining the network contributes to a robust ecosystemone that offers the most advanced, cloud-based informatics solutions to help accelerate precision medicine studies across all therapeutic areas.

By providing access to Invicros novel software solutions, researchers will easily gain insights from complex biological data at each drug discovery and development phase, stated Mr. Chris Fuller, Vice President of Software for Invicro. The advanced and collaborative capabilities offered by Invicro and Accenture will improve operational efficiencies and help streamline drug discovery efforts by using a data-driven approach.

Invicros capabilities will be available to life sciences companies within a common informatics framework that handles core infrastructure requirements such as data ingestion and cleansing, security and IP management, request management workflow, enterprise search, data governance, and collaboration environments.

Imaging data is enabling some incredible opportunities in early drug discovery, yet there remain challenges around the effective image management, interpretation, and sharing, said Joe Donahue, managing director, Accenture Life Sciences. I look forward to working closely with Invicro to leverage their capabilities to help address these challenges which will, ultimately, lead to better outcomes for patients.

About Invicro Headquartered in Boston, MA, Invicro was founded in 2008 and today has offices, laboratories and clinics around the world, from coast-to-coast within the United States, to Europe and Asia that support leading pharmaceutical and biotechnology companies and top research universities. Invicros multi-disciplinary team provides solutions to help enhance the discovery and development of life-changing drugs across all stages of the drug development pipeline (Phase 0-IV), leveraging all imaging modalities within a broad scope of therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicros quantitative biomarker services, advanced analytics tools, and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant and iPACS.

Invicro is a Konica Minolta company and part of their precision medicine initiative, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. Along with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. Visit http://www.invicro.com for more information

About Konica Minolta Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and societytoday and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customers most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrows issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005690/en/

Read the original post:
Invicro LLC Joins Accenture's INTIENT Network to Help Advance Innovation in Drug Discovery and Scientific Research - BioSpace

Overview:

Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.

Get Sample Copy Of The Report@ https://www.trendsmarketresearch.com/report/sample/9807

Majority of nanomedicines prescribedcurrently, allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

Market Analysis:

The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Regional Analysis:

The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis:

Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Request For Report Discount@ https://www.trendsmarketresearch.com/report/discount/9807

Key Players:

Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis:

At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits:

The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Report Analysis@ https://www.trendsmarketresearch.com/report/analysis/IR/nanomedicine-market

View more :Healthcare, Pharmaceuticals, & Medical Devices Report Insights

Continue reading here:
Nanomedicine Market Healthy Pace throughout the Forecast by 2023 - Crypto News Byte